Quantitative evaluation of cellular internalization of polymeric nanoparticles within laryngeal cancer cells and immune cells for enhanced drug delivery

Li-Juan Ma1*, Ruichao Niu2†, Xi Wu1, Jun Wu1, En Zhou1, Xu-Ping Xiao1 and Jie Chen2*

Abstract
Clinical translation of poly (lactic-co-glycolic acid) (PLGA)-based nanomedicine is limited, partly because of the poor delivery efficiency resulting from non-specific phagocytosis by phagocytes. Understanding the nanoparticle interplay between cancer cells and immune cells remains largely elusive. In this study, a quantitative investigation on cellular internalization of fluorescent PLGA particles (100 nm, 500 nm, and 1 µm) against laryngeal carcinoma cells with or without monocytes/macrophages in monoculture or co-culture systems was first performed. PLGA particles at concentrations of 5–20 µg/mL show superior biocompatibility except for 500 nm and 1 µm PLGA particles at 20 µg/mL slightly reduce cell viability. Microscopic observation has discovered all three sizes of particles are effectively ingested by both cancer cells and macrophages; however, quantitative fluorescence examination has disclosed that the uptake index of cancer cells (mean intracellular particle fluorescence per cancer cell normalized to that of per macrophage) is substantially declined for all PLGA particles in co-cultures compared to that in monocultures (1.35–1.05, 1.50–0.59, and 1.4–0.47 for 100 nm, 500 nm, and 1 µm particles, respectively). Quantitative analysis using flow cytometry further confirmed the reduced uptake index of cancer cells in co-cultures, but higher particle counts per macrophage. It has also been found that the formation of multinucleated giant cells via the fusion of macrophages increased after PLGA treatment, which could be further exploited as a potential approach for tumor drug delivery. Overall, these findings provide new insights into the interaction of nanoparticle-immune-cancer cells, which may facilitate the application of PLGA-based nanocarriers for the treatment of laryngeal carcinoma.

Keywords: Cellular uptake, Co-culture, Cytotoxicity, Laryngeal cancer, Polymeric particles, Cell fusion

Introduction
Cancer is one of the leading causes of mortality worldwide with around 10 million new cases of death reported in 2018 [1]. Laryngeal carcinoma (cancerous cells arise from the larynx) is the second most common malignancy of head and neck squamous cell carcinomas (HNSCCs), accounting for about 180,000 new cases and 95,000 deaths in 2018 [2]. Currently, targeted drugs are developed as an optional treatment for challenges introduced by traditional therapies such as surgery, radiotherapy, and chemotherapy [3]. Scientific efforts have been expedited to improve drug targeting and efficacy and reduce unwanted side effects by developing, for example, novel drug nanocarriers (i.e., microneedles), personalized anticancer drugs, and therapeutic antibody targeted delivery systems [4].
Nanocarriers have been widely utilized to load anticancer drugs such as cisplatin, paclitaxel, and docetaxel to improve their water solubility, bioavailability, and stability for improved drug delivery and efficacy [3, 4]. In general, nanoparticle (NP)-based drug delivery permits the delivery of a broad range of other substances (e.g., proteins, antibodies, vaccines, and nucleic acids) to specific regions of the body in both animal models and patients [4, 5]. However, the so-called enhanced permeability and retention (EPR) effect has resulted in considerably varying targeting efficiency among different types of cancer [6]. Recent evidence suggests that deposition of nanodrug-carriers (here gold NPs) to tumors preferentially depends on the process of transcytosis [7], a type of biological transcellular transport, in which substances/NPs are transferred across the cells from one side to another including the courses of endocytosis, vesicular transfer, and exocytosis. It should, however, be noted that the contradictory outcomes regarding the mechanisms of targeted drug delivery emphasize of critical importance for understanding the basis of cellular interaction with nanodrugs or NPs utilizing multiple experimental strategies ranging from in vitro cell culture to ex vivo tissue culture and in vivo animal study.

Numerous nanocarriers like liposomes, albumin NPs (NPs), silica NPs, and poly(lactic-co-glycolic acid) (PLGA) have been clinically employed to treat different types of cancer including laryngeal carcinoma [4]. Polymeric-based NPs such as micelles and PLGA hold great potential in biomedical applications because of their versatile formulations of nano-drug through simple mixing or covalent conjugation, excellent ability of self-assembly, high capability of drug loading, and biocompatibility [8, 9]. For example, polyethylene glycol (PEG)-coated PLGA nanocarriers loaded with doxorubicin and indocyanine green enable synergistic chemo-photothermal therapy for breast cancer [10]. Also, both in vitro and in vivo studies have shown that cisplatin-loaded micelles exhibit excellent anticancer activity against HNSCC orthotopic tumors (i.e., SAS-L1 and HSC-2) [11]. Although several polymeric-based nano-drug-carriers like PLGA and micelles have been approved for clinical use or are being evaluated in clinical trials [4, 6], many more polymeric nano-drugs are under preclinical investigation with different head and neck cancer cell lines and xenograft tumor models of animals [11–14].

Scientific evidence has highlighted the significance of host immunological responses to nano-drug-carriers, because once those NPs once enter the body, they become unavoidably recognized by the immune system. Macrophages are considered the first line of cellular host defense, specializing in the neutralization and clearing of allergens, microorganisms, and foreign particles (e.g., nanocarriers) via phagocytosis and consequent priming of immune responses. Most of the novel-designed nanocarriers have failed to targeted delivery to specific diseased regions or tumors in vivo because of the efficient accumulation of NPs in the mononuclear phagocyte system (MPS), such as Kupffer cells in the liver and red pulp macrophages in the spleen [15]. Hence, understanding the mechanisms of cellular uptake of NPs by immune cells like monocytes and macrophages is crucial as it determines the lifetime of nanocarriers in relevant tissues and biological fluids. Emerging in vitro cell co-culture system has, therefore, gradually attracted increasing attention within the fields of nanomedicine and toxicology because of the increasing demand for achieving more meaningful results that can better reflect the in vivo condition [16]. Indeed, co-culture systems have been proven to exhibit a realistic situation in mimicking healthy and diseased tissue states [17] and have been reliably utilized in NP cellular uptake and drug absorption studies [18–21]. Utilization of co-culture cancer cell and immune cell models generally offers a suitable platform for probing the uptake routes and mechanisms of these nanomaterials into cells, which may facilitate the design of nanocarriers that are better targeted to cancerous cells while simultaneously reducing NP phagocytosis. Therefore, it is of essential importance to determine the uptake efficiency and fate of NPs in cancer cells in the presence of immune cells. Most nanocarriers have been designed to have diameters of 50–200 nm to harness the EPR effect and prolong blood circulation, while larger NPs (>500 nm) are reported to be efficiently cleared by the MPS [6]. PLGA, an FDA approved nano-carrier, in different sizes (100, 500, and 1000 nm) was thus selected to investigate the uptake capabilities of UM-SCC-17A (a classical laryngeal squamous carcinoma cell line) [22] and THP-1 (a human acute monocytic cell line) cells. Several in vitro studies have applied PLGA nanocarriers to deliver drugs to kill HNSCC cancer cells in monocultures [12, 13, 23], this is the first study to probe the uptake efficiency and mechanism of NP uptake by immune cells and laryngeal cancer cells synchronously in a co-culture model by employing different sizes of PLGA, which might provide a fundamental basis for the development of novel safe-by-design nanomedicine for HNSCC therapy.

Materials and methods

Materials

Three commercialized PLGA particles (Sigma-Aldrich) with different sizes including 100 nm, 500 nm, and 1000 nm were used in this study. All the particles were loaded with green fluorophores with optical excitation and emission (ex/em) wavelengths of 460 nm and 500 nm. All the particles were received in a form of
powder and were suspended in distilled water with a final concentration of 10 mg/mL for further use. Hydrodynamic diameters and zeta potentials of three particles were carried out by dynamic light scattering (DLS) conducted with a Malvern Zeta Sizer Nano instrument (Malvern Instruments Ltd., Malvern, UK). The stock suspensions of each particle were 1:100 diluted in 80 µl distilled water for DLS measurement. Following the indication from the manufacturer, 3 repeated measurements for each particle were obtained.

Cell cultures of UM-SCC-17A and THP-1 and particle exposure

The human laryngeal carcinoma cell line UM-SCC-17A and human monocyte/macrophage cell line THP-1 purchased from Sigma-Aldrich, USA and Shanghai Hengya Biotechnology Company (Shanghai, China), respectively, were used to build the in vitro model in this study. UM-SCC-17A cells and THP-1 cells were cultured in either DMEM [22] or RPMI-1640 cell culture medium supplemented with 10% FBS (Gibco, Germany) and 1% Penicillin–Streptomycin solution (Gibco, Germany) at 37 °C with 5% CO2. THP-1 cells were exposed to 100 nM Phorbol 12-myristate 13-acetate (PMA) (Sigma, USA) solutions for 72 h before cell seeding to differentiate into macrophages. Both of the cells were passaged using 0.5% trypsin–EDTA every 3 days, and the cell morphology was checked every day to ensure the health of the cells.

Cells were seeded in 24-well plates at the density of 0.1 × 10⁶ cells/well for mono-cultured cells for WST-1 and LDH assay, or on sterile glass coverslip in 24-well plates for fluorescent microscopy. For the co-cultured model, UM-SCC-17A cells were first seeded in 24-well plates at a density of 50,000/well overnight and then added with 50,000/well THP-1 cells. Particles were suspended in 500 µl either respective cell-culture medium for mono-cultured UM-SCC-17A and THP-1 cells or 1:1 mixed cell-culture medium for co-cultured cells and exposed to cell samples for 24 h with final concentrations of 5, 10, and 20 µg/mL for WST-1 and LDH assay or 10 µg/mL for fluorescent microscopy.

For FACS measurement, cells were seed in 12-well plates in the same manner as described before at a density of 250,000 cells/well, or 125,000 cells/well each for the co-cultured model. Cells were grown in 1 mL cell-culture medium overnight and exposed to PLGA particles at a final concentration of 10 µg/mL for 24 h.

Cell viability assay

Cell viability was determined by the cell proliferation reagent WST-1 kit (Roche, Germany) according to the instructions from the manufacturer. Briefly, the WST-1 solution was 1:10 diluted in either respective cell-culture medium for mono-culture UM-SCC-17A or THP-1, or 1:1 mixed cell-culture medium for co-cultured cells. The supernatant was drained off after the exposure, and cells were incubated with 500 µl working solution of WST-1 assay at 37 °C for 30 min. Samples were collected and centrifuged at 14,000 rpm for 10 min to remove the particles. The absorbance (OD value) of the solutions were measured under the wavelength of 450 nm using Infinite®F200 (Tecan, USA). The absorbance values were corrected by subtracting the value of a blank sample containing only the WST-1 working solution, and the relative cell viabilities were compared with the untreated control sample.

Cell membrane leakage assay

Lactate dehydrogenase (LDH) release was measured using a commercial cytotoxicity detection kit (LDH) (Roche, Germany) to determine the cytotoxicity by PLGA particles. The supernatant of the cells was collected 24 h after the exposure, centrifuged at 14,000 rpm for 10 min, and 1:10 diluted in 200 µl complete cell-culture medium. The positive control was defined as the total release of LDH by incubating the cells with 0.2% Triton X-100 at 37 °C for 15 min, and 1:50 diluted in 200 µl complete cell-culture medium. Samples were incubated with 100 working solutions of LDH assay for 30 min at room temperature, and the reaction was stopped using 50 µl 1% HCl. The absorbance at the wavelength of 492 nm was measured using Infinite®F200 (Tecan, USA), and relative LDH concentrations were calculated according to the following equation

\[
\text{Relative LDH concentration} = \frac{(\text{sample OD} - \text{blank OD})}{(\text{positive control OD} - \text{blank OD})} \times 5 \times 100%.
\]

Fluorescence microscopy

Cells were visualized by Hoechst staining for localization of the particles under the fluorescence microscope. Cells were washed with PBS for 3 times after 24 h exposure of the particles and incubated with 4% formaldehyde for 10 min at room temperature. After fixed with formaldehyde, cells were then incubated with 200 µl staining solution containing 1:1000 diluted Hoechst and 1% BSA in PBS for 30 min. Then, the coverslips were moved onto a glass slide upside-down and maintained with a drop of DAKO fluorescence anti-fade agent for visualization. Four optical channels were set with a fluorescence microscope, including bright filed for cell morphology, DAPI for cell nuclei, and GFP for particles. Exposure times of the particle channel for each
fluorescent picture were recorded and used for homog-
enization of the fluorescence intensity across different
particles, and intracellular particles were calculated by
fluorescence intensity using randomly selected areas by
ImageJ (https://imagej.nih.gov/ij/). The uptake index
across different particles was compared between mono-
cultured or co-cultured UM-SCC-17A cells. Briefly, the
mean fluorescent intensity (MFI) of internalized parti-
cles was calculated in, e.g., 50 cells for each cell type,
which was determined as the subtraction value between
the total fluorescence intensity ($I_{\text{total}}$) of a specific area
and the autofluorescence ($I_{\text{auto}}$) of the same-sized area
in the particle-free region equation [24, 25]. The uptake
index of cancer cells was determined by the MFI of
UM-SCC-17A normalized to that of THP-1 cells in
either mono-cultured or co-cultured model. The calcu-
lation was performed following the equation below:

$$\text{uptake index} = \frac{I_{\text{total}1} - I_{\text{auto}1} (\text{MFI}_{\text{UM-SCC-17A}})}{I_{\text{total}2} - I_{\text{auto}2} (\text{MFI}_{\text{THP-1}})}$$

Fluorescence-activated cell sorting (FACS)
The fluorescence-activated cell sorting (FACS) was
performed to measure the uptake capability of three
particles. Cells were washed with PBS for three times
to remove the cell medium and dissociative particles
24 h after the exposure and incubated with 200 µL 0.5%
trypsin–EDTA (Gibco, Germany) at 37 °C for 4 min to
remove the cells from the plate. Then, the reaction was
stopped by adding 2 ml complete cell culture medium,
and the cell suspension was moved to a glass tube for
FACS measurement and centrifuged for 5 min at 300 × G,
4 °C. The supernatant was discharged gently, and cells
were suspended in 200 µL PBS and preserved on ice. Live
cells were first gated from debris and dead cells using for-
cing buffer (three times washing for remove the residual
particles with cells, the cell culture supernatant, wash-
tively, which the latter indicated their highly monodis-
perse standards. All particles were vortexed and then
characterized with independent triplications, and data were
presented as mean ± standard deviation (STD). Results
for comparing multiple-group results or two-group
results, respectively. All the experiments were per-
formed with independent triplications, and data were
presented as mean ± standard deviation (STD). Results
with $p$ value < 0.05 (*) and $p < 0.01$ (**) were considered
significant.

Results and discussion
Characterization of poly(lactic-co-glycolic acid) particles
Fluorescence micrographs of PLGA particles (Fig. 1a,b,c)
exhibited robust fluorescent intensity and no significant
decreases in fluorescence signals over the course of 14
d after preparation (Additional file 1: S1), suggesting a
relatively homogenous size distribution and high fluo-
rescence stability. As denoted by the supplier, 100, 500,
and 1000 nm PLGA particles showed the sizes of about
80.6 ± 19.3 nm, 542.6 ± 128.3 nm, and 951.9 ± 237.5 nm
(Fig. 1d,e,f), respectively. According to zeta potential
measurements, the average surface charges on the parti-
cles were found to be $-20.6 ± 5.3$, $-17 ± 4.6$, and
$-16.5 ± 3.5$ with poly dispersity index of 0.057, 0.056,
and 0.062 for 100, 500, and 1000 nm particles, respec-
tively, which the latter indicated their highly monodis-
perse standards. All particles were vortexed and then
sonicated in a water bath for 5 min to largely eliminate
the particle aggregation. However, small peaks corre-
sponding to 100 and 1000 nm particles were observed
with diameters of about 4–6 µm because of the inevitable
particle aggregation in very small amounts (about 3–4%).
Evaluation of cell viability and cytotoxicity

Due to their superb biocompatibility and biodegradability, PLGA particles have been approved by the FDA and European Medicine Agency for biomedical applications [27, 28]. PLGA particles have thus been currently used in the clinic and are widely applied in preclinical studies as nanocarriers delivering drugs to specific diseased regions or tumors. However, the targeting efficiency and therapeutic efficacy of PLGA particles are hindered, at least partially, by the immune system. For example, high particle phagocytosis by Kupffer cells in the liver greatly restricted the nano-drug-carriers from entering the tumor site [15]. Therefore, it is of vital importance to establish advanced in vitro models to study the interaction among cancer cells, immune cells and particles to better mimic the in vivo situation of drug delivery. UM-SCC-17A is a unique laryngeal squamous carcinoma cell line isolated from the primary larynx cancer specimen [29]. However, information regarding its in vitro cellular uptake efficiency in co-culture systems (e.g., co-incubation of macrophages and cancer cells) is still insufficient, an issue that needs to be addressed to improve the prediction ability of in vivo responses. Moreover, it has been proven that particle size and surface coating play an important role in the delivery capability to solid tumors, diseased sites, and cancer cells in animal models and cell cultures [30–33]. Here, we thus applied three sizes of PLGA to UM-SCC-17A carcinoma cells to investigate the effects of particle size on cellular uptake and intracellular distribution in monoculture and co-culture systems.

This study determined the cell viability using WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) method for monoculture THP-1 and UM-SCC-17A cells, as well as a co-culture of both types of cells. Despite no obvious cell death was occurred in groups treated with 100 and 500 nm PLGA at all tested concentrations, 500 nm and 1 µm PLGA particles at the highest concentration (20 µg/mL) significantly reduced the cell viability in monoculture UM-SCC-17A cells (Fig. 2a). As expected, the THP-1 cell viability was not significantly affected after 24 h incubation with all three types of PLGA at concentrations of 5–20 µg/mL (> 95% viability in comparison with untreated cells, whose viability is considered as 100%, Fig. 2b). Identical to the results of monoculture UM-SCC-17A cells, cell viability in the co-culture system was not altered by the presence of 100 and 500 nm PLGA particles in three dosages used here, while it significantly declined in the group treated with 20 µg/mL 1 µm PLGA (Fig. 2c).

Evaluation of particle cytotoxicity utilizing the LDH assay is to determine leakage of the cell membrane by measuring the amount of extracellular LDH [9]. The release of this cytoplasmic enzyme into the cell culture supernatant is characteristic of cellular membrane
injury, leading to irreversible cell death. Despite the slight enhancement of LDH levels with higher dosages in monoculture UM-SCC-17A cells treated with various doses of 1 µm PLGA, no distinct cytotoxicity to the cells was observed even at the highest concentration of 20 µg/mL (Fig. 3a). Not surprisingly, all three sizes of PLGA used here at various dosages were unable to induce substantial LDH release into the supernatant, indicating the insignificant toxic effects to monoculture THP-1 cells, which is also highly consistent with the cell viability results described above (Fig. 3b). In the co-culture experiments, all the particles with different concentrations showed excellent biocompatibility toward both cells in terms of released LDH levels (Fig. 3c). In general, the broad particle size range, from 100 nm to 1 µm, that was used here covers the typical sizes of nanocarriers (50–200 nm), such as liposomes, micelles, dendrimers, polymers, and mini-cells. This range also covers sub-micron sized particles (500 nm particles can be still considered as NPs, e.g., particles with sizes about 500 nm have same clearance pathways in the lung as those of NPs in 10–100 nm [34] and micron-sized 1 µm. None of these PLGA particles showed any obvious cytotoxicity to the THP-1 and/or UM-SCC-17A cells in monoculture and co-culture systems, except for the 500 nm and 1 µm PLGA particles at the highest concentration against UM-SCC-17A and co-culture cells (but more than 85% of cells are survived), indicating that they are favorable for applications in drug delivery systems.

**Capabilities of cellular uptake of PLGA in monoculture and co-culture systems**

Figure 4 shows the cell morphology (Fig. 4a,d,g), cell nuclei and 100 nm NPs (Fig. 4b,e,h), and merged magnified images (Fig. 4c,f,i) in monoculture and co-culture systems. No particles were observed in the untreated cells of the control group (Additional file 1: S2). Massive large-sized 100 nm PLGA NPs agglomerates were
observed in the cell cytoplasm of the macrophage monocytole culture cells (Fig. 4c). Meanwhile, monoculture UM-SCC-17A exhibited an excellent uptake capability of 100 nm PLGA, proven by the bright green fluorescence signals observed inside the cell membrane (Fig. 4f). To better illustrate the intracellular accumulation of PLGA particles in THP-1 or UM-SCC-17A cells and extracellular particles in the co-cultures, overlays of bright field images with fluorescence images were applied as in Additional file 1: S3). In co-culture system, both cell types are differentiable in terms of morphology and cell size in the bright field images, in which macrophages displayed a round shape and small size, whereas the cancer cells exhibited a large size and elongated shape. However, the cancer cells showed insufficient cellular ingestion due to the high uptake of 100 nm PLGA by macrophages in the co-cultured system. This is expected because macrophages are considered as an efficient and specific type of immune cells to perform the phagocytosis function for clearing foreign microorganisms, allergens, and particles.

Similarly, Fig. 5 and Fig. 6 show qualitative analysis of cellular uptake ability of 500 nm and 1 µm PLGA particles in single-cell or mixed cell cultures, respectively. It is noteworthy that both cell morphologies were not altered after treatment with different sizes of PLGA particles at the concentration of 10 mg/mL used here (Fig. 4a,d,g, Fig. 5a,d,g, and Fig. 6a,d,g). 500 nm and 1 µm PLGA particles displayed stronger fluorescence intensity in sole UM-SCC-17A cells (Fig. 5e,f, and Fig. 6e,f) than that in sole THP-1 cells (Fig. 5b,c, and Fig. 6b,c). In co-culture incubations (Fig. 5h,i, and Fig. 6h,i), there are apparent signal decreases in cancer cells, in which the particle fluorescent intensity was found to be lower than that of the macrophages. Macrophages phagocytosed all types of particles rapidly and effectively so that cancer cells cannot ingest enough particles in co-culture system. To quantify the effect of phagocytosis on the uptake capacity by cancer cells for different sizes of PLGA particles, a semi-quantitative optical analysis was performed. Briefly, the particle fluorescence intensities were calculated on
the basis of, for example, 50 individual particle-laden cells to achieve a mean value for both cell types, and the uptake index of cancer cells was determined by averaging the intracellular particle fluorescent intensity per cancer cell normalized to that of macrophages (Fig. 7). In monoculture, the cancer cell uptake index for 100 nm PLGA was found to be about 1.34 ± 0.19, suggesting that the cancer cells have ingested more particles than those ingested by macrophages in the single-cell culture (Fig. 7). This is not surprising because of the high level of viscosity of PLGA particles and the larger size of laryngeal cancer cells. Similarly, 500 nm and 1 µm PLGA were also greatly internalized by cancer cells with uptake indices of approximately 1.5 ± 0.25 and 1.4 ± 0.31, respectively, in monoculture. The uptake indices for large particles were substantially declined (0.59 ± 0.12 and 0.47 ± 0.1) in the presence of macrophages in co-culture systems. Meanwhile, identical cellular internalization capabilities for both cell types after 24 h incubation of 100 nm PLGA particles in the mixed cell culture. Overall, the results accumulated here suggested that the ingestion of particles by cancer cells and macrophages might depend on different routes of uptake pathway in single-cell culture and co-culture environment. Moreover, the presence of macrophages reduced the cellular internalization of PLGA particles by cancer cells particularly for large ones, a biological event that has been observed in vivo nanomedicine drug delivery studies [3, 15].

**Quantification of cellular uptake by flow cytometry**

Flow cytometry is widely used to determine of particle-cell interplay in a quantitative manner, for example, the size-dependent uptake of polystyrene particles with sizes ranging from 20 to 1000 nm by dendritic cells in vivo [35]. FACS was thus utilized for analysis of the percentage of NP-positive cells and particle number in those NP-positive cells in monoculture and co-culture systems. Then, average NP counts in a single cell were calculated by determining the total fluorescence intensity in particle-laden cells normalized to the fluorescence of total
applied dose. For example, about 70% of 500 nm PLGA was deposited in the cancer cells, whereas the residual was kept in the supernatant of cell cultures (Additional file 1: S4). This fluorescence intensity measured by a Tecan reader was then compared to the average/total FACS signals (FITC signal values of P5 and P6 in Fig. 8,) to estimate the particle number in the co-culture system. As seeded in the co-cultured cells, about half of the cells were recognized as macrophages and the rest were considered as cancer cells. It was observed that approximately 13,000 of single 100 nm PLGA particles accumulated in cancer cells and 9700 particles in macrophages (Fig. 8i) in the monoculture, consistent with the above microscopic examinations. A much lower particle number (164 ± 30 and 45 ± 15) was ingested by monocultured cancer cells for 500 nm and 1 µm PLGA, with a slightly lower particle count in the respective macrophages (Fig. 8i). The number of particles ingested by single cells is in great agreement with the literature records [24]; for instance, an average 2500 of gold NPs coated with...
Cetyltrimethylammonium bromide were deposited in epithelial cells, while PEG-modified gold NPs only had a few tens per cell [36]. In co-culture systems, unexpectedly, there is a slight increase of 100 nm particle number in cancer cells, despite a higher enhancement of NP internalization by macrophage. Comparing to the uptake index in the single-cell to mixed cell culture, it also reduces about 25% for 100 nm PLGA particles. The uptake indices were found to significantly decline with around 2.5 and 3 folds reduction in co-cultured system for 500 nm and 1 µm PLGA, respectively (Fig. 8i). Generally, it was found that the existence of macrophages largely affects the uptake ability of cancer cells especially for large particles, which is also in excellent agreement with the above observations.

Currently, different uptake pathways by cancer cells in ingesting particles with different sizes and surface modifications like clathrin-mediated endocytosis, caveolae-mediated endocytosis, clathrin- and caveolae-independent endocytosis, micropinocytosis, and macropinocytosis have been claimed in the literature [37]. For instance, it has been proved that iron oxide aggregates with a size of < 200 nm are taken up by MCF-7 cells through the clathrin-mediated endocytosis, whereas larger aggregates tend to be ingested via macropinocytosis [38]. Another study has demonstrated that 100 nm plain polystyrene particles tended to be taken up mainly...
through macropinocytosis, whereas the internalization of carboxylated polystyrene particles prefer to occur via the clathrin-mediated endocytic route [25]. Phagocytosis is a classical uptake pathway for immune cells such as neutrophils, dendritic cells, and most importantly monocytes/macrophages. The uptake pathways tightly depend on various parameters of drug delivery vesicles, e.g., the particle size, chemical composition, surface modification, proteins in the culture environment, as well as cell type. Usually, multiple uptake pathways can be involved in particle ingestion such as the caveolae-mediated endocytosis, clathrin-mediated endocytosis, and macropinocytosis, which has been found to participate in cellular internalization of 300–400 nm chitosan NPs in human HepG2 cells [39]. It has also been observed that 63 nm cholesterol-modified pullulan NPs enter into the human hepatocellular carcinoma (HepG2) cells via macropinocytosis and clathrin-mediated endocytosis [40]. Several previous studies showed that PLGA particle cell uptake involves different endocytic pathways, in which clathrin-independent endocytosis is the main route responsible for the internalization of PLGA in in vitro models [23, 24, 37]. Nevertheless, once they entered into the cells, PLGA particles applied here were highly potentially entrapped by the endo-lysosomal system consisting of early endosomes, recycling endosomes, late endosomes, and lysosomes [41]. It should be noted, however, that there is a lack of studies showing the cellular uptake mechanisms in co- or tri-cultured systems in vitro, a notion that has to be probe in the future.

**Induction of cell fusion by PLGA NPs**

Extensive scientific evidence has shown that the fusion of monocytes/macrophages into multinucleated giant cells (MGCs) occurred in a broad range of biological processes [42, 43]. Generally, implantation of biomaterials into the body causes a foreign body response characterized by the fusion of macrophages into MGCs and fibrotic encapsulation [44]. A wide type of human and murine primary cells like alveolar macrophages, splenic macrophages, microglia, bone-marrow-derived macrophages, and blood monocytes, as well as cell lines such as RAW264.7 and UG3 were also frequently observed to form MGCs in vitro [26, 45]. It is well-known that the macrophages form a fusogenic phenotype when they are unable to ingest foreign materials via phagocytosis because of the large size of particles or implants. So far, it is unclear whether in vitro macrophage cell fusion relates to the size in the range 100–1000 nm, which can be easily phagocytized. Here, the cell fusions were observed in all groups by microscopic examination (Fig. 9). The cellular fusion was confirmed only when multiple nuclei were found to share the same cytoplasm in both fluorescence images and bright-field images. Spontaneous formation of giant cells by THP-1 cells was occurred in the control group without particle treatment (Fig. 9a), with a fusion percentage of about 10% of the total cells (Fig. 9h), as reported in the literature [46]. Size-dependent cellular fusion was found for 100 and 500 nm PLGA particles, whereas 1 µm PLGA-induced insignificant enhancement of fusions in monoculture. This may be due to the small number of 1 µm PLGA particles exposed to cells (approximately 60 particles exposed to each cell at a concentration of 10 µg/mL). When the macrophages were co-cultured with cancer cells, the percentages of MGC formation were increased in all groups in comparison with the corresponding monoculture groups. In particular, there is a significant increment of cellular fusion for 1 µm PLGA (19%) in the mixed cell culture. The most prominent increase in fusion occurred in co-cultured 500 nm PLGA particles, which might be attributed to the large size of particles and sufficient particle numbers ingested per cell.

The molecular machinery involved in macrophage fusion has been widely probed, achieving substantial progress [43]. For example, the formation of macrophage fusion receptors CD47 and CD44 together allowed mediating the process of macrophage fusion, and subsequent the differentiation of giant cells [42] and miR-223 delivery by a NP vesicle permitted attenuating it [47]. Hence, further study should focus on the determination of key molecules in regulating particle-induced macrophage fusion and the dominant receptors expressed in the giant cell membrane. Another important concern is the fate of MGCs. It is believed that MGCs fused with particles or stimuli might subsequently experience the process of apoptosis or necrosis [48]. This may lead to the release of undigested particles or other giant materials to the other cells in vitro or biological tissues in vivo, further inducing the long-term inflammatory response or granulomas.

On the other hand, the macrophage fusion itself may be benefit for NP drug delivery, for example, in tumorous tissues, the re-release of drugs from macrophages to the cancer cells might represent an enhanced tumor killing ability. More importantly, future nanomedicine study should address how to exploit the application of macrophage fusion for nanocarrier drug delivery to improved disease diagnosis and therapy. This is because not only macrophages an abundant type of immune cells in the body with the excellent uptake ability of nano-drugs, but also they may be used in targeted gene delivery for repair of injured tissues.
Conclusion
To the best of our knowledge, this study first reported the competitive cellular uptake of PLGA particles with sizes ranging from 100 nm to 1 µm in co-cultured UM-SCC-17A laryngeal cancer cells and THP-1 monocytes/macrophages. The data collected here proved that immune cells may alter/lower the particle internalization by cancer cells in vitro, which is similar to the previous findings in in vivo nanocarrier drug delivery studies. Size-dependent and cell culture-related macrophage cellular fusion caused by PLGA particles has also been demonstrated here. Future studies should probe the uptake mechanism in co-cultured systems and design novel approaches to achieve a higher uptake index for laryngeal cancer cells in the presence of phagocytes. Moreover, elaborate evaluation of intracellular trafficking and fate of nano-drug-carriers in co- or tri-cultured systems in 3D, which better mimic the in vivo conditions, is needed prior to the utilization of animal studies in vivo and even in clinical trials.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s11671-021-03498-y.

Additional file 1: Fig S1. Fluorescent intensity of various PLGA particles over two weeks after preparation. Fig S2. No particles can be observed in the untreated cells of control group. Fig S3. Co-localization of bright field images (b) with fluorescent images (c) displays the intracellular accumulation of PLGA particles in THP-1 cells (red arrows) or UM-SCC-17A cells (white arrows) and extracellular particles (yellow arrows) in the co-cultures (d). Fig S4. Percentages of PLGA particles deposited in the cells (intracellular particles) normalized to the applied particles (the total dose) at 24 h after incubation.

Abbreviations
PLGA: Poly(lactic-co-glycolic acid); HNSCC: Head and neck squamous cell carcinoma; EPR: Enhanced permeability and retention; NPs: Nanoparticles; ICG: Indocyanine green; MPS: Mononuclear phagocyte system; LDH: Lactate dehydrogenase; DAPI: 4',6-diamidino-2-phenylindole; THP-1: Human monocyte cell line; UM-SCC-17A: Human laryngeal cell line.
dehydrogenase; FACS. Fluorescence-activated cell sorting; MGC: Multinucleated giant cells; DLS: Dynamic light scattering.

Acknowledgements

Not applicable

Authors’ contributions

Conceptualization was contributed by L-JM, NR, and JC; methodology was contributed by XW and JW; formal analysis was contributed by L-JM, NR, XW, and JW; investigation was contributed by EZ, X-PX; writing original draft was contributed by L-JM and NR; writing, review and editing were contributed by XW, JW, EZ, X-PX, and JC; supervision was contributed by L-JM and JC; funding acquisition was contributed by L-JM. The manuscript was written through the contributions of all authors. All authors have approved the final version of the manuscript.

Funding

This work was supported by the Natural Science Foundation of Hunan Province (No.2019JJ0088).

Availability of data and materials

All data generated or analyzed during this study are included in this published article [and its supplementary information files].

Competing interests

The authors declare no competing of interest.

Received: 11 November 2020   Accepted: 16 February 2021

Published online: 02 March 2021

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:39-424
2. Larynx Cancer Factsheet (PDF), Global Cancer Observatory. https://gco.iarc.fr/today/data/factsheets/cancers/14-Larynx-fact-sheet.pdf. (Revised on 8 November 2019). Accessed 15 Sep 2020
3. Pelazv B, Alexiou CH, Alvarez-Puebla RA, Alves F, Andrews AM, Ashraf S, Baloght L P, Ballerini L, Bestetti A, Brendel C et al (2017) Diverse applications of nanomedicine. ACS Nano 11:2313–2381
4. Shi J, Kantoff PW, Wooster R, Farokhzad OC (2017) Cancer nanomedicine: progress challenges and opportunities. Nat Rev Cancer 17:20–37
5. Elham A, Abolfazl A, Nosratollah Z (2015) Chrysin‑loaded PLGA‑PEG nanoparticles for the release of hydrogen sulfide under visible light with therapeutic nanoparticle in cancer cells. Appl Nanosci 8:115–124
6. Gupta P, Singh M, Kumar R, Belz J, Shanker R, Dwivedi PD, Sridhar S, Singh SP (2018) Synthesis and in vitro studies of PLGA-DTX nanocomjugate as potential drug delivery vehicle for oral cancer. Int J Nanomed 13:67–69
7. Masloub SM, Elmalahy MH, Sabry D, Mohamed WS, Ahmed SH (2016) Comparative evaluation of PLGA nanoparticle delivery system for 5-fluorouracil and curcumin on squamous cell carcinoma. Arch Oral Biol 64:1–10
8. Reh H, Gao C, Zhou L, Liu M, Xie C, Lu W (2015) EGFR-targeted poly(ethylene glycol)-distearoylphosphatidylethanolamine micelle loaded with paclitaxel for laryngeal cancer: preparation characterization and in vitro evaluation. Drug Deliv 22:785–794
9. Dai Q, Wilhelm S, Ding D, Syed A, Sindhwani S, Zhang Y, Chen YY, MacMillan P, Chan WCW (2018) Quantifying the ligand-coated nanoparticle delivery to cancer cells in solid tumors. ACS Nano 12:8423–8435
10. Stone V, Johnston H, Schins RP (2009) Development of in vitro systems for nanotoxicology: methodological considerations. Crit Rev Toxicol 39:613–626
11. Kampfer AAM, Urban P, Giora S, Kanase N, Stone V, Kinsner-Ovakainen A (2017) Development of an &lt;ita&gt;in vitro&lt;/ita&gt; co-culture model to mimic the human intestine in healthy and diseased state. Toxicol In Vitro 45:31–43
12. Baulerams T, Feijao T, Goncalves A, Shahbazi MA, Liu ZH, Barrias C, Oliveira MJ, Granja P, Santos HA, Sarmento B (2020) Colorectal cancer triple co-culture spheroïd model to assess the biocompatibility and anticancer properties of polymeric nanoparticles. J Control Release 323:398–411
13. Costa EC, Gaspar VM, Marques JG, Coutinho P, Correia U (2013) Evaluation of nanoparticle uptake in co-culture cancer models. PloS ONE 8:7
14. Georqantzopoulou A, Serchi T, Cambier S, Leclercq CC, Renaut J, Shao J, Krußwenski M, Lentzen E, Gryan P, Eswara S et al (2016) Effects of silver nanoparticles and ions on a co-culture model for the gastrointestinal epithelium. Part Fibre Toxicol 13:9
15. Meng W, Kallinteri P, Walker DA, Parker TL, Garnett MC (2007) Evaluation of poly (glicerin-adipate) nanoparticle uptake in an in vitro 3D brain tumor co-culture model. Exp Biol Med (Maywood) 232:1100–1108
16. Brenner JC, Graham MP, Kumar R, Saunders LM, Kupfer R, Lyons RH, Bradford CR, Carey TE (2010) Genotyping of 73 Umm‑Sc head and neck squamous cell carcinoma cell lines. Head Neck Sci Spec 3:417–426
17. Gao C, Pan J, Lu W, Zhang M, Zhou L, Tian J (2009) In-vitro evaluation of paclitaxel-loaded MPEG-PLGA nanoparticles on laryngeal cancer cells. Anticancer Drugs 20:802–814
18. Gal N, Massalha S, Samuelly-Nafa Q, Weis J (2015) Effects of particle uptake encapsulation and localization in cancer cells on intracellular applications. Med Eng Phys 37:478–483
19. Jiang X, Musyanovych A, Rocker C, Landfester K, Malander V, Nienhaus GU (2011) Specific effects of surface carbonyl groups on anionic polystyrene particles in their interactions with mesenchymal stem cells. Nanoscale 3:2028–2035
20. Trout KL, Holian A (2019) Factors influencing multinucleated giant cell formation in vitro. Immunobiology 224:834–842
21. Kumari A, Yadav SK, Yadav SC (2010) Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces 75:1–1828
22. Hafezi Z, Alebooye F, Mokhtarzadeh A et al (2016) Evaluation of anticancer activity of PLGA nanoparticles containing crocetin. Artif Cells Nanomed Biotechnol 45:955–960
23. Carey TE, Van Dyke DL, Worsham MJ, Bradford CR, Babu VR, Schwartz DR, Hsu S, Baker SR (1989) Characterization of human laryngeal primary and metastatic squamous cell carcinoma cell lines UMC-17A and UMC-17B. Cancer Res 49:1696–1704
24. Vishwakarma SK, Bardia A, Lakkireddy C, Paspala SA, Habeeb MA, Khan AA (2018) Real-time cellular and molecular dynamics of bi-metallic self-therapeutic nanoparticle in cancer cells. Appl Nanosci 8:115–124
25. Samuel MS, Shah SS, Bhattacharya J, Subramaniam K, Pradeep Singh ND (2018) Adsorption of Pb(ii) from aqueous solution using a magnetic chitosan/graphene oxide composite and its toxicity studies. Int J Biol Macromol 115:142–1150
26. Parthiban C, Pavithra M, Reddy LVK, Sen D, Samuel MS, Singh NDP (2018) Synthesis and in vitro studies of PLGA-DTX nanocomjugate as potential drug delivery vehicle for oral cancer. Int J Nanomed 13:67–69
27. Ma et al. Nanoscale Res Lett (2021) 16:40 Page 13 of 14
34. Todoroff J, Vanbever R (2011) Fate of nanomedicines in the lungs. Curr
Opin Colloid Interface 16:246–254
35. Blank F, Stumbles PA, Seydoux E, Holt PG, Fink A, Rothen-Rutishauser B,
Strickland DH, von Garnier C (2013) Size-dependent uptake of particles
by pulmonary antigen-presenting cell populations and trafficking to
regional lymph nodes. Am J Respir Cell Mol Biol 49:67–77
36. Rosman C, Pierat S, Henkel A, Tarantola M, Schneider D, Sunnick E, Jan-
shoff A, Sonnichsen C (2012) A new approach to assess gold nanoparticle
uptake by mammalian cells: combining optical dark-field and transmis-
sion electron microscopy. Small 8:3683–3690
37. Foroozandeh P, Azz AA (2018) Insight into cellular uptake and intracel-
lular trafficking of nanoparticles. Nanoscale Res Lett 13:339
38. Calero M, Chiappi M, Lazar-Carrillo A, Rodriguez MJ, Chichon FJ, Crosbie-
Staunton K, Prins-Mello A, Volkov Y, Villanueva A, Carrascosa JL (2015)
Characterization of interaction of magnetic nanoparticles with breast
cancer cells. J Nanobiotechnol 13:16
39. Nam HY, Kwon SM, Chung H, Lee SY, Kwon SH, Jeon H, Kim Y, Park JH,
Kim J, Her S et al (2009) Cellular uptake mechanism and intracellular fate
of hydrophobically modified glycol chitosan nanoparticles. J Control
Release 135:259–267
40. Jiang L, Li X, Liu L, Zhang Q (2013) Cellular uptake mechanism and
intracellular fate of hydrophobically modified pullulan nanoparticles. Int J
Nanomedicine 8:1825–1834
41. Panyam J, Zhou W Z, Prabha S, Lakhsetewar V (2002) Rapid
endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles:
implications for drug and gene delivery FASEB J 16:1217–1226
42. Vignery A (2000) Osteoclasts and giant cells: macrophage-macrophage
fusion mechanism. Int J Exp Pathol 81:291–304
43. Helming L, Gordon S (2009) Molecular mediators of macrophage fusion.
Trends Cell Biol 19:514–522
44. Jay SM, Skokos EA, Zeng J, Khoo K, Kyriakides TR (2010) Macrophage
fusion leading to foreign body giant cell formation persists under phago-
cytic stimulation by microspheres in vitro and in vivo in mouse models. J
Biomed Mater Res A 93:189–199
45. Lemaire I, Falzoni S, Zhang B, Pellegrati P, Di Virgilio F (2011) The P2X(7)
Receptor and Pannexin-1 Are Both Required for the Promotion of Multi-
nucleated Macrophages by the Inflammatory Cytokine GM-CSF. Journal
of Immunology 187:3878–3887
46. Chiozzi P, Sanz JM, Ferrari D, Falzoni S, Alleotti A, Buell GN, Collo G, Di Vir-
gilio F (1997) Spontaneous cell fusion in macrophage cultures expressing
high levels of the P2Z/P2X7 receptor. J Cell Biol 138:697–706
47. Moore LB, Sawyer AJ, Sauzier-Sawyer J, Saltzman WM, Krykides TR
(2016) Nanoparticle delivery of miR-223 to attenuate macrophage fusion.
Biomaterials 89:127–135
48. Wang W, Li Y, Liu X, Jin M, Du H, Liu Y, Huang P, Zhou X, Yuan L, Sun Z
(2013) Multinucleation and cell dysfunction induced by amorphous silica
nanoparticles in an L-02 human hepatic cell line. Int J Nanomedicine
8:3533–3541

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.